News
Thu, 04 May 2023 05:34:00 -0400
Thu, 04 May 2023 05:34:00 -0400
Financial report for the period 1 January 2023 to 31 March 2023
|
PROFIT AND LOSS |
Q1 2023 |
Q1 2022 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
7,693 |
6,339 |
27% |
25% |
|
Operating profit |
3,605 |
2,888 |
31% |
28% |
|
|
|
|
|
|
|
Net profit |
2,856 |
2,143 |
39% |
N/A |
|
Diluted earnings per share (in USD) |
1.27 |
0.94 |
41% |
N/A |
* CER: Constant exchange rates (average 2022).
**For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.0 = DKK 6.93735 and the period-end exchange rate of USD 1.0 = DKK 6.84920.
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the sales growth in the first three months of 2023. The growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, particularly in the US where the prescription trend for Wegovy® highlights the high unmet need for people living with obesity. The sales momentum and continued expansion of the supply capacity have enabled us to raise the outlook for the full year."
On 4 May 2023 at 13.00 CEST, corresponding to 07.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.